WELCOME TO THE 4th ANNUAL

PATIENT GROUP PATHWAY MODEL
TO ACCESSING CANCER CLINICAL
TRIALS & REAL-WORLD EVIDENCE
METHODOLOGIES CONFERENCE

WITH A SPECIAL FOCUS THIS YEAR ON
CLINICAL TRIALS IN THE ERA OF PRECISION MEDICINE.

Date: Oct 21, 2020

Time: 8:00 to 4:30

COLORECTAL CANCER CANADA

COLORECTAL CANCER CANADA

Whether you are an oncology healthcare professional, researcher, trial sponsor, representative of a clinical trial network, contract research organization, industry representative, government representative, or if you are engaged in health technology assessment or real world evidence, a cancer patient, caregiver, or you just want to keep up to date with the latest developments in the field of cancer clinical trials in Canada, this conference is a must for you!

INSIGHTS

IN EVOLUTIONARY

TRENDS

This seminal event will acknowledge the evolutionary trends in the field of precision medicine and provide an insight into the dynamics of patient-centricity and value-based care as adapted to new trial designs.

FIND OUT MORE

CENTRAL TO THE DISCUSSION

CENTRAL TO THE DISCUSSION

At this year’s virtual event, will be the evolution of cancer clinical trials in the era of precision medicine in both the Canadian and international context, as well as the development of new and novel initiatives to ensure patient access to clinical trials so that ultimately the right patients will have access to the right drugs at the right time.

if you envision precision medicine as the future standard of care… JOIN US!

if you envision precision medicine as the future standard of care… JOIN US!

Our amazing working group endeavoured tirelessly to finalize the Canadian Clinical Trials Stakeholder Charter taking into account all input we received over the past two years. We look forward to presenting it at the conference and discussing modalities for ensuring its adoption by all clinical trial stakeholders in Canada.



REGISTER NOW

We have some great international speakers lined up to ensure that you are not only well informed about these new initiatives, but fully engaged in the process. We look forward to your participation and input so that we can all ensure that Canada remains a premier place to conduct cancer clinical trials.